9 March 2022
Proveca announces new partnership with ExCEEd Orphan
Proveca has announced its new partnership with ExCEEd Orphan to commercialise and distribute Sialanar® exclusively in Central and Eastern Europe (CEE).
Under the terms of the agreement, ExCEEd Orphan will have exclusive rights to seek reimbursement, distribute and market Sialanar® within its paediatric indication in several CEE countries where they operate as experts in rare diseases. It is estimated that approximately 2,850 children with neurodisabilities suffer from sialorrhea in the CEE region.
Sialanar® (320 mcg/ml glycopyrronium, oral solution) received a European Paediatric Use Marketing Authorisation (PUMA) on 15th September 2016 for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
Dr Simon Bryson, CEO and founder of Proveca Ltd, commented: “We are delighted to announce this agreement with ExCEEd Orphan to make Sialanar available to children with neurodisabilities who suffer from sialorrhoea. As in many countries there is such an unmet need to manage this condition and improve quality of life to patients and their carers. We are looking forward to working with ExCEEd Orphan, who have a strong track record of launching orphan medicines within this region. As Sialanar is now available for patients in many countries in Europe, this agreement is in line with our commercialisation strategy in order to optimise global market access for our products outside the large European markets.”
Jiri Hermanek, Chief Executive Officer and Founding Partner of ExCEEd Orphan, commented: “We are really pleased to announce partnership with Proveca to bring Sialanar to children with neurodisabilities suffering from sialorrhoea in CEE countries. Sialanar addressing this serious unmet medical need fits perfectly with the long-term strategy of ExCEEd Orphan, focusing on launching innovative medications for rare diseases in CEE region. We are looking forward to working with Proveca to make Sialanar available to as many patients as possible through our partnership with leading Paediatric Neurology centres in our countries.”